<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31959864</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis - Results from the ALS Registry Swabia.</ArticleTitle><Pagination><StartPage>736</StartPage><MedlinePgn>736</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">736</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-57744-x</ELocationID><Abstract><AbstractText>We investigated the associations of serum concentration of insulin-like growth factor 1 (IGF1) with risk and prognosis of ALS in the ALS registry (October 2010-June 2014, median follow-up 67.6 months) in a case-control and cohort study, respectively. Serum samples were measured for IGF-1. Information on covariates was collected by standardized questionnaire. We applied conditional logistic regression to appraise the risk and Cox proportional hazards models to appraise the prognostic value of IGF-1. Data of 294 ALS patients (mean age 65.4 (SD 11.0) years, 60.2% men) and 504 controls were included in the case-control study. Median serum IGF-1 concentrations were slightly higher in ALS cases than in controls (101 vs. 99.5&#x2009;ng/ml). IGF-1 concentrations were not associated with ALS risk in the fully adjusted model (top vs. bottom quartile: OR 1.16; 95%-CI 0.73-1.84, p for trend&#x2009;=&#x2009;0.44). Among 293 ALS cases (mean age 65.5 (SD 10.5) years, 56.8% men) 243 died during follow-up. We found a statistically significant inverse association between continuous IGF-1 concentrations and survival (p&#x2009;=&#x2009;0.01). Very high values IGF-1 were associated with a better prognosis of ALS suggesting that functions related to IGF-1 could be involved in survival.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagel</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6185-8535</Identifier><AffiliationInfo><Affiliation>Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peter</LastName><ForeName>Raphael S</ForeName><Initials>RS</Initials><Identifier Source="ORCID">0000-0003-4310-9500</Identifier><AffiliationInfo><Affiliation>Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbohm</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koenig</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Deutsches Herzzentrum M&#xfc;nchen, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>INSERM U1118, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothenbacher</LastName><ForeName>Dietrich</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany. dietrich.rothenbacher@uni-ulm.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C583557">IGF1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>67763-96-6</RegistryNumber><NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007334" MajorTopicYN="Y">Insulin-Like Growth Factor I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31959864</ArticleId><ArticleId IdType="pmc">PMC6971302</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-57744-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-57744-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ludolph AC, Brettschneider J, Weishaupt JH. Amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2012;25:530&#x2013;535. doi: 10.1097/WCO.0b013e328356d328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e328356d328</ArticleId><ArticleId IdType="pubmed">22918486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter RS, et al. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur. J. Epidemiol. 2017;32:901&#x2013;908. doi: 10.1007/s10654-017-0318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0318-z</ArticleId><ArticleId IdType="pubmed">28975435</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G, et al. Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis - results from a population- based ALS registry in Germany. Sci. Rep. 2017;7:4374. doi: 10.1038/s41598-017-04706-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04706-5</ArticleId><ArticleId IdType="pmc">PMC5491500</ArticleId><ArticleId IdType="pubmed">28663573</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SE, Park C-Y, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit. Rev. Clin. Lab. Sci. 2015;52:180&#x2013;190. doi: 10.3109/10408363.2015.1023429.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10408363.2015.1023429</ArticleId><ArticleId IdType="pubmed">26042993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauskolb S, Dombert B, Sendtner M. Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis. Neurobiol. Dis. 2017;97:103&#x2013;113. doi: 10.1016/j.nbd.2016.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.04.007</ArticleId><ArticleId IdType="pubmed">27142684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis ME, et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp. Neurol. 1993;124:73&#x2013;88. doi: 10.1006/exnr.1993.1177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1993.1177</ArticleId><ArticleId IdType="pubmed">8282084</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Aleman I, Barrios V, Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology. 1998;50:772&#x2013;776. doi: 10.1212/WNL.50.3.772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.50.3.772</ArticleId><ArticleId IdType="pubmed">9521273</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese K. Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease. Neural Regen. Res. 2015;10:518&#x2013;528. doi: 10.4103/1673-5374.155427.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.155427</ArticleId><ArticleId IdType="pmc">PMC4424733</ArticleId><ArticleId IdType="pubmed">26170801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen D, et al. The role of insulin-like growth factor 1 in ALS cell and mouse models: A mitochondrial protector. Brain Res. Bull. 2018;144:1&#x2013;13. doi: 10.1016/j.brainresbull.2018.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2018.09.015</ArticleId><ArticleId IdType="pubmed">30414993</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005;168:193&#x2013;199. doi: 10.1083/jcb.200407021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200407021</ArticleId><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. 2010;18:2075&#x2013;2084. doi: 10.1038/mt.2010.206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.206</ArticleId><ArticleId IdType="pmc">PMC2997594</ArticleId><ArticleId IdType="pubmed">20859261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore AC, et al. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007;1185:256&#x2013;265. doi: 10.1016/j.brainres.2007.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.034</ArticleId><ArticleId IdType="pmc">PMC2265207</ArticleId><ArticleId IdType="pubmed">17963733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakowski SA, Schuyler AD, Feldman EL. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2009;10:63&#x2013;73. doi: 10.1080/17482960802160370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802160370</ArticleId><ArticleId IdType="pmc">PMC3211070</ArticleId><ArticleId IdType="pubmed">18608100</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G, &#xdc;nal H, Rosenbohm A, Ludolph AC, Rothenbacher D. Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia. BMC Neurol. 2013;13:22. doi: 10.1186/1471-2377-13-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-13-22</ArticleId><ArticleId IdType="pmc">PMC3582473</ArticleId><ArticleId IdType="pubmed">23414001</ArticleId></ArticleIdList></Reference><Reference><Citation>Uenal H, et al. Incidence and Geographical Variation of Amyotrophic Lateral Sclerosis (ALS) in Southern Germany &#x2013; Completeness of the ALS Registry Swabia. PLoS One. 2014;9:e93932. doi: 10.1371/journal.pone.0093932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0093932</ArticleId><ArticleId IdType="pmc">PMC3983245</ArticleId><ArticleId IdType="pubmed">24722455</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, et al. Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J. Neurol. 2017;264:749&#x2013;757. doi: 10.1007/s00415-017-8413-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8413-3</ArticleId><ArticleId IdType="pubmed">28220290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosback S, et al. Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm. IGF Res. 2007;17:472&#x2013;479. doi: 10.1016/j.ghir.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ghir.2007.06.002</ArticleId><ArticleId IdType="pubmed">17697791</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauverd M, Mitchell JD, Wokke JHJ, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst. Rev. 2012;11:CD002064.</Citation><ArticleIdList><ArticleId IdType="pubmed">23152212</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, et al. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2018;17:1043&#x2013;1052. doi: 10.1016/S1474-4422(18)30320-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30320-X</ArticleId><ArticleId IdType="pmc">PMC6415539</ArticleId><ArticleId IdType="pubmed">30337273</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergani A, et al. A mutation in the dynein heavy chain gene compensates for energy deficit of mutant SOD1 mice and increases potentially neuroprotective IGF-1. Mol. Neurodegener. 2011;6:26. doi: 10.1186/1750-1326-6-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-26</ArticleId><ArticleId IdType="pmc">PMC3111394</ArticleId><ArticleId IdType="pubmed">21521523</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, et al. Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients. Muscle Nerve. 2012;45:200&#x2013;208. doi: 10.1002/mus.22288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22288</ArticleId><ArticleId IdType="pmc">PMC3306791</ArticleId><ArticleId IdType="pubmed">22246875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, et al. Intramuscular Delivery of scAAV9-hIGF1 Prolongs Survival in the hSOD1G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase. Mol. Neurobiol. 2018;55:682&#x2013;695. doi: 10.1007/s12035-016-0335-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0335-z</ArticleId><ArticleId IdType="pubmed">27995572</ArticleId></ArticleIdList></Reference><Reference><Citation>Messi ML, Clark HM, Prevette DM, Oppenheim RW, Delbono O. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS. Exp. Neurol. 2007;207:52&#x2013;63. doi: 10.1016/j.expneurol.2007.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.05.016</ArticleId><ArticleId IdType="pmc">PMC2043146</ArticleId><ArticleId IdType="pubmed">17597610</ArticleId></ArticleIdList></Reference><Reference><Citation>Dor&#xe9; S, Kar S, Quirion R. Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends Neurosci. 1997;20:326&#x2013;331. doi: 10.1016/S0166-2236(96)01036-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(96)01036-3</ArticleId><ArticleId IdType="pubmed">9246719</ArticleId></ArticleIdList></Reference><Reference><Citation>Musar&#xf2; A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature. 1999;400:581&#x2013;585. doi: 10.1038/23060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/23060</ArticleId><ArticleId IdType="pubmed">10448862</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua K, Forbes ME, Lichtenwalner RJ, Sonntag WE, Riddle DR. Adult-onset deficiency in growth hormone and insulin-like growth factor-I alters oligodendrocyte turnover in the corpus callosum. Glia. 2009;57:1062&#x2013;1071. doi: 10.1002/glia.20829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20829</ArticleId><ArticleId IdType="pmc">PMC2696576</ArticleId><ArticleId IdType="pubmed">19115393</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, et al. Impairments to the GH-IGF-I axis in hSOD1G93A mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis. Endocrinology. 2012;153:3735&#x2013;3746. doi: 10.1210/en.2011-2171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2011-2171</ArticleId><ArticleId IdType="pubmed">22621959</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhari A, Gupta R, Patel S, Velingkaar N, Kondratov R. Cryptochromes regulate IGF-1 production and signaling through control of JAK2-dependent STAT5B phosphorylation. Mol. Biol. Cell. 2017;28:834&#x2013;842. doi: 10.1091/mbc.e16-08-0624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e16-08-0624</ArticleId><ArticleId IdType="pmc">PMC5349790</ArticleId><ArticleId IdType="pubmed">28100634</ArticleId></ArticleIdList></Reference><Reference><Citation>Breit A, et al. Insulin-like growth factor-1 acts as a zeitgeber on hypothalamic circadian clock gene expression via glycogen synthase kinase-3&#x3b2; signaling. J. Biol. Chem. 2018;293:17278&#x2013;17290. doi: 10.1074/jbc.RA118.004429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.004429</ArticleId><ArticleId IdType="pmc">PMC6222112</ArticleId><ArticleId IdType="pubmed">30217816</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorges M, et al. Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2017;88:1033&#x2013;1041. doi: 10.1136/jnnp-2017-315795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315795</ArticleId><ArticleId IdType="pubmed">28596251</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CP, Grimberg A. Insulin-Like Growth Factor-I is a Marker for the Nutritional State. Pediatr. Endocrinol. Rev. 2015;13:499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576178</ArticleId><ArticleId IdType="pubmed">26841638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, et al. Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018;75:600&#x2013;607. doi: 10.1001/jamaneurol.2017.5129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.5129</ArticleId><ArticleId IdType="pmc">PMC5885207</ArticleId><ArticleId IdType="pubmed">29482216</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>